Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 01 02 2019
revised: 21 02 2019
accepted: 26 02 2019
pubmed: 11 3 2019
medline: 20 2 2020
entrez: 11 3 2019
Statut: ppublish

Résumé

Nonstructural protein 1 (NS1) plays a crucial function in the replication, spread, and pathogenesis of influenza virus by inhibiting the host innate immune response. Here we report the discovery and optimization of novel pyrazolopyridine NS1 antagonists that can potently inhibit influenza A/PR/8/34 replication in MDCK cells, rescue MDCK cells from cytopathic effects of seasonal influenza A strains, reverse NS1-dependent inhibition of IFN-β gene expression, and suppress the slow growth phenotype in NS1-expressing yeast. These pyrazolopyridines will enable researchers to investigate NS1 function during infection and how antagonists can be utilized in the next generation of treatments for influenza infection.

Identifiants

pubmed: 30852083
pii: S0960-894X(19)30111-8
doi: 10.1016/j.bmcl.2019.02.027
pmc: PMC8290212
mid: NIHMS1523408
pii:
doi:

Substances chimiques

Antiviral Agents 0
INS1 protein, influenza virus 0
Pyrazoles 0
Pyridines 0
Viral Nonstructural Proteins 0
pyrazolopyridine 0
Interferon-beta 77238-31-4

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1113-1119

Subventions

Organisme : Intramural NIH HHS
ID : Z99 TR999999
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201100019C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201100019I
Pays : United States
Organisme : NIMH NIH HHS
ID : R03 MH085680
Pays : United States
Organisme : NIAID NIH HHS
ID : R44 AI084244
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Mol Cell. 1998 Jun;1(7):991-1000
pubmed: 9651582
Vet Microbiol. 2000 May 22;74(1-2):29-46
pubmed: 10799776
Life Sci II. 1972 Nov 22;11(22):1081-6
pubmed: 4663809
Annu Rev Pathol. 2008;3:499-522
pubmed: 18039138
Eur J Med Chem. 2014 Jan;71:81-90
pubmed: 24287556
J Gen Virol. 2014 Dec;95(Pt 12):2594-2611
pubmed: 25182164
J Antimicrob Chemother. 2014 May;69(5):1298-310
pubmed: 24458510
Antiviral Res. 2013 Sep;99(3):409-16
pubmed: 23796981
J Biol Chem. 2018 Sep 21;293(38):14659-14668
pubmed: 30076219
N Engl J Med. 2005 Sep 29;353(13):1363-73
pubmed: 16192481
Curr Top Microbiol Immunol. 2015;386:121-47
pubmed: 25038940
J Gen Virol. 2008 Oct;89(Pt 10):2359-2376
pubmed: 18796704
Nature. 2012 Mar 14;483(7390):428-33
pubmed: 22419161
Vet Microbiol. 2000 May 22;74(1-2):133-9
pubmed: 10799785
J Virol. 1994 Apr;68(4):2425-32
pubmed: 7908060
EMBO J. 1999 Apr 15;18(8):2273-83
pubmed: 10205180
Bioorg Med Chem. 2012 Jan 1;20(1):487-97
pubmed: 22099257
J Virol. 2000 Dec;74(24):11566-73
pubmed: 11090154
J Virol. 2009 Feb;83(4):1881-91
pubmed: 19052087
Curr Top Microbiol Immunol. 2015;386:73-107
pubmed: 25007846
Mayo Clin Proc. 2004 Apr;79(4):523-30; quiz 530
pubmed: 15065617
J Biomol Screen. 2012 Apr;17(4):448-59
pubmed: 22223052
EMBO J. 1994 Feb 1;13(3):704-12
pubmed: 8313914
Arch Virol. 1994;138(3-4):299-314
pubmed: 7998836
J Virol. 2017 Jan 3;91(2):
pubmed: 27807226
N Engl J Med. 2018 Sep 6;379(10):913-923
pubmed: 30184455
Curr Med Chem. 2011;18(35):5466-75
pubmed: 22087838
J Virol. 2002 Nov;76(21):11166-71
pubmed: 12368362
J Gen Virol. 2011 Jan;92(Pt 1):60-70
pubmed: 20881091
Curr Opin Virol. 2015 Jun;12:1-6
pubmed: 25638592
N Engl J Med. 2006 Nov 23;355(21):2174-7
pubmed: 17124014

Auteurs

Samarjit Patnaik (S)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States. Electronic address: patnaiks@mail.nih.gov.

Dipanwita Basu (D)

Department of Microbiology, Immunology and Cancer Biology, University of Virginia School of Medicine, 1300 Jefferson Park Ave., Charlottesville, VA 22908, United States.

Noel Southall (N)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.

Seameen Dehdashti (S)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.

Kanny K Wan (KK)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.

Wei Zheng (W)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.

Marc Ferrer (M)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.

Mercedes Taylor (M)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States.

Daniel A Engel (DA)

Alexander BioDiscoveries, LLC, 530 Forrest Rd., Charlottesville, VA 22902, United States. Electronic address: dae2s@virginia.edu.

Juan Jose Marugan (JJ)

Division of Pre-Clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, United States. Electronic address: maruganj@mail.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH